8-KLeadership ChangesShareholder Matters

JOHNSON & JOHNSON 8-K Report, Executive Changes (May 1, 2023)

Filed May 1, 2023For Securities:JNJ

Summary

This 8-K filing from Johnson & Johnson reports on the outcomes of their 2023 Annual Meeting of Shareholders held on April 27, 2023. A key event detailed is the departure of Thibaut Mongon from his Executive Vice President role to fully assume his CEO position at Kenvue Inc., following Kenvue's initial public offering. This transition marks a significant step in the separation and independent operation of the consumer health business. Shareholders overwhelmingly supported the re-election of all 12 director nominees and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor. The company also received advisory approval for its executive compensation and the annual frequency of such advisory votes. However, two shareholder proposals, one requesting a Vaccine Pricing Report and another on the impact of extended patent exclusivities on product access, did not receive sufficient support for approval. This filing provides clarity on corporate governance matters and key leadership changes impacting the company's structure.

Key Highlights

  • 1Thibaut Mongon has stepped down as EVP, Worldwide Chairman, Consumer Health and member of the Executive Committee to focus on his role as CEO of Kenvue Inc., post-Kenvue's IPO.
  • 2All 12 director nominees were re-elected to the Board of Directors.
  • 3Shareholders approved, on an advisory basis, Johnson & Johnson's executive compensation.
  • 4Shareholders approved, on an advisory basis, an annual vote on executive compensation.
  • 5PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for fiscal year 2023.
  • 6A shareholder proposal for a Vaccine Pricing Report was not approved.
  • 7A shareholder proposal regarding the Impact of Extended Patent Exclusivities on Product Access was not approved.

Frequently Asked Questions

Thibaut Mongon's departure from his Executive Vice President role signifies a crucial step in the ongoing separation and independent operation of Kenvue Inc., Johnson & Johnson's consumer health business, which recently completed its initial public offering. His full focus will now be on leading Kenvue as its CEO.

Shareholders overwhelmingly re-elected all director nominees and ratified the appointment of PricewaterhouseCoopers LLP as the auditor. They also provided advisory approval for executive compensation and opted for an annual advisory vote on compensation. However, two shareholder proposals concerning vaccine pricing and patent exclusivities did not pass.

Following shareholder feedback, the Board of Directors has decided to include an advisory vote on the compensation of executive officers in the company's proxy statement every year until the next required frequency vote, which is expected by the 2029 Annual Meeting of Shareholders.

Two shareholder proposals failed to gain approval: one requesting a report on Vaccine Pricing and another seeking a report on the Impact of Extended Patent Exclusivities on Product Access.